This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
Bayer has snapped up certain licensing rights from ProStrakan to develop and market the Scotland-based speciality pharmaceuticals group’s testosterone replacement gel Tostran in 65 countries. Bayer ...
BEDMINSTER, N.J., June 17 New data from a 12-month,international, multi-center study showed that treatment for low testosteronewith Tostran(R), a topical, metered dose 2% testosterone gel, ...
Scotland’s ProStrakan Group has acquired the outright worldwide rights for two of its leading products – Rectogesic (glyceryl trinitate), an ointment for chronic anal fissures, and Tostran ...
Testosterone treatment appears to improve the underlying problem in some men with type 2 diabetes, according to a study funded by U.K. drugmaker ProStrakan. The problem — called "insulin resistance" — ...
A Scottish pharmaceutical firm has concluded a deal to market its testosterone gel across 65 countries. Borders-based ProStrakan has agreed the exclusive licence for Tostran with Bayer Schering Pharma ...
Nov 27 (Reuters) - UK speciality pharmaceuticals company ProStrakan Group Plc on Thursday said it gave an exclusive license to Bayer Schering Pharma to develop and market its testosterone replacement ...
Product will be launched in the U.S. during early 2011. ProStrakan is eligible for a milestone payment of $12.5 million from Endo Pharmaceuticals as a result of FDA approving the testosterone ...
ProStrakan, the Borders-based pharmaceutical company, yesterday said it gave an exclusive licence to Bayer Schering Pharma to develop and market its testosterone replacement gel Tostran in 65 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results